definition of mucositis
Mucositis is defined as inflammatory and/or ulcerative lesions of the oral and/or gastrointestinal tract. Infectious disease, immune deficiency and medications can be causative. One of the major causes of mucositis is high-dose cancer therapy.
Alimentary tract mucositis refers to the expression of mucosal injury across the continuum of oral and gastrointestinal mucosa, from the mouth to the anus. mucositis incidence and associated complications incidence of oral mucositis in patients receiving high-dose head and neck radiation
The incidence of World Health Organization (WHO) grade 3 or 4 oral mucositis in patients receiving high-dose head and neck radiation (e.g. 6000-7000 Gy) to the oral cavity approaches 85%, but all treated patients have some degree of oral mucositis. Mucositis is one of the prime limiting factors of chemoradiation for advanced head and neck carcinoma. The oral pain associated with the lesion frequently leads to the need for enteral nutritional support with or without use of a feeding tube or gastrostomy, as well as use of opioids. The objective of this approach is to maintain dose intensity throughout the entire radiation regimen.
incidence of oral and gastrointestinal mucositis in patients undergoing hematopoietic stem cell transplantation
The incidence of WHO grade 3 or 4 oral mucositis can be as high as 75% in patients undergoing hematopoietic stem cell transplantation (HSCT), depending on the intensity of the conditioning regimen used and the use of methotrexate prophylactically to prevent graft-versus-host disease. Management of oral and gastrointestinal mucositis is one of the main challenges during the period of aplasia, with risk of sepsis related to the degree of mucosal barrier breakdown and depth of marrow suppression.
incidence of mucositis associated with standard multicycle chemotherapy (with or without radiotherapy) for non-Hodgkin's lymphoma and breast, lung and colorectal cancers Data relative to risk of developing grade 3 or 4 oral mucositis and diarrhea are presented in Table 1 . For all tumor sites, chemotherapy with 5-fluorouracil (5-FU), capecitabine or tegafur leads to a high rate (e.g. 20-50%) of alimentary tract mucositis. Phase I modeling of drug dose and sequence may be of benefit to future patients in this regard. Chemotherapy with Although it is not clear whether the pathogenesis of these lesions is comparable with mucositis caused by conventional cancer therapies, current mucositis management guidelines as described below may be useful. Further research is needed relative to optimal strategies for prevention and treatment of these mucosal toxicities.
risk factors for mucositis
Risk of mucositis has classically been directly associated with modality, intensity and route of delivery of the cancer therapy. Combination therapy (e.g. head and neck radiation with concurrent chemotherapy) may increase the severity of oral mucositis. Interestingly, the incidence and severity of acute mucosal toxicity has not generally been significantly reduced by utilization of state-of-the-science radiation technologies (e.g. volumetric-modulated arc therapy).
While this modeling continues to be valid, there appear to be additional risk factors (e.g. genetic polymorphisms) in some cohorts that account for the degree of clinical expression. Further study of these more recently defined factors will likely strategically advance the pathobiological model in relation to clinical expression of the toxicity.
Among patient-related risk factors, co-morbidities (e.g. malnutrition) can contribute important risk. All patients should be screened for nutritional risk and early enteral nutrition initiated in the event that swallowing difficulties develop. In addition, patients who develop clinically significant salivary hypofunction/xerostomia due to head and neck radiation and/or antiemetic drugs may experience increased discomfort from oral mucositis. Hydration of the oral mucosa and topical pain interventions such as local anesthetics should be considered. Grade 2 = Moderate pain; not interfering with oral intake; modified diet indicated Grade 3 = Severe pain; interfering with oral intake Grade 4 = Life-threatening consequences; urgent intervention indicated Grade 5 = Death Most of the scales that are utilized for clinical care incorporate the collective measurement of oral symptoms, signs and functional disturbances. In comparison, some scales are primarily centered in clinician-based observation of mucosal tissue injury (e.g. erythema, ulceration). These latter scales have particular value in clinical trial-based assessment of oral mucositis.
In contrast, there are a limited number of instruments available for assessment of gastrointestinal mucositis. These scales typically measure indirect outcomes of mucosal injury, including diarrhea. However, interpretation of such data can be confounded by other clinical conditions and interventions that also contribute to the event being measured. New technologies may lead to enhanced assessment strategies for gastrointestinal mucositis.
mucositis management guidelines
Oral and gastrointestinal mucositis management guidelines are summarized below, as developed by the Mucositis Study Group of MASCC/ISOO. Palifermin (keratinocyte growth factor-1) i.v. has been studied in solid tumor cohorts, although additional studies are warranted prior to reaching clinical recommendations.
One study suggested that palifermin may be useful in a dose of 40 lg/kg/day for 3 days for prevention of oral mucositis in patients receiving bolus 5-FU plus leucovorin. Another study reported the efficacy and safety of single-dose palifermin (180 lg per kg body weight) administered 3 days before each chemotherapy cycle in reducing oral mucositis during multicycle chemotherapy regimens for sarcoma. This dosing schema reduced the incidence and severity of oral mucositis and was well tolerated overall, although most subjects developed thickening of the oral mucosa. As the authors indicate, further research is needed to delineate whether palifermin-associated reduction in oral mucositis will enhance adherence to chemotherapy regimens.
Two studies published in June 2011 in the Journal of Clinical Oncology added further support to the potential benefit of palifermin in the head and neck cancer setting. In patients undergoing postoperative radiochemotherapy for head and neck, 51% of patients receiving weekly palifermin 120 lg/kg developed severe oral mucositis, vs 67% in the placebo cohort. The second recent study was conducted in definitive chemotherapy regimens of locally advanced head and neck cancer. Patients received 180 lg/ kg palifermin or placebo before starting chemoradiotherapy and then once weekly for 7 weeks. The palifermin recipients experienced delayed median time to severe oral mucositis (35 days vs 47 days) and shortened median duration of severe oral mucositis (5 days vs 26 days). The authors of both studies suggest that further study in these cohorts is needed.
high-dose chemotherapy with or without total body irradiation plus HSCT: prevention.
Palifermin is recommended in a dose of 60 lg/kg/day for 3 days before conditioning treatment and for 3 days posttransplant for the prevention of oral mucositis in patients with hematological malignancies receiving high-dose chemotherapy and total body irradiation with autologous stem cell transplantation [ Chlorhexidine oral rinses are not recommended to treat established oral mucositis [II, A]. Chlorhexidine oral rinses may be an option, however, as a topical antimicrobial to enhance treatment of oral infection based on professional judgment topical agents also utilized for supportive care treatment oral mucositis. In addition to the approaches described above, some clinicians utilize approved devices for mucositis management. These topically administered agents include Gelclair Ò , Caphasol Ò and BioteneÒ. The research evidence base on which these practices are based is limited. However, the agents appear to have an effective safety profile and may be of benefit for some patients. There continues to be key progress relative to the molecular pathobiology, computational biology and clinical impact of mucosal injury in cancer patients that may generate strategic research and clinical advances in the future. These advances will likely result in revisions in the MASCC/ISOO mucositis guidelines in the next 2-5 years. Examples of novel, important future opportunities based on the recent advances include the following.
Delineation of predictive models that could enhance the ability of clinicians to identify prospectively which solid tumor patients are at highest risk for development of clinically significant oral and/or gastrointestinal mucositis. Recent research relative to identification of systemic and/or mucosal tissue-based genetic susceptibility for mucositis represents an important example of this modeling. Molecular relationships between degree of tumor response and extent of acute mucosal toxicity. Enhanced technologies to assess severity of gastrointestinal mucositis. Utilization of single or combination topical and/or systemic preventive and treatment interventions, once several molecularly targeted therapies for mucositis are approved for clinical use. Increased clinical recognition of the importance of Grade II oral and/or gastrointestinal mucositis, in the context of symptom burdens that are experienced by cancer patients.
Potential impact of emerging targeted cancer therapies on the incidence and severity of alimentary tract mucositis, including potential unique pathobiology as well as clinical trajectory.
There is also need and opportunity for the conduct of clinical trials relative to devices that have been initially reported as effective and safe in reducing oral mucositis incidence and severity in cancer patients. Such studies are essential for several reasons including (i) validation of current commercial claims; (ii) identification of which patients may experience highest benefit; and (iii) assessment of feasibility for use by these patients.
It is important that basic, translational and clinical research continue relative to preventive and treatment modalities for oral and gastrointestinal mucositis. This collective research could lead to approval of new drugs and devices for which evidence-based, cancer patient-specific identification of risk and associated management of mucositis could become possible. 
